Biocon Limited (BSE: 532523 | NSE: BIOCON), a global biopharmaceutical company focused on innovation-driven therapies, announced its consolidated results for the third quarter ended December 31, 2025, highlighting steady revenue growth, margin expansion, and key strategic milestones. Operating revenue for Q3 FY26 rose 9% year-on-year to ₹4,173 crore.
Core EBITDA increased 21% to ₹1,221 crore, delivering operating margins of 29%. Reported EBITDA stood at ₹951 crore, also up 21%, with margins of 22%. Profit before tax (before exceptional items) grew 64% to ₹226 crore, while net profit surged to ₹144 crore.
During the quarter, Biocon completed important corporate actions aimed at simplifying its structure and strengthening its financial position. The company fully integrated Biocon Biologics as a wholly owned subsidiary, valuing the business at approximately USD 5.5 billion. Over the past eight months, Biocon raised nearly USD 1 billion through two Qualified Institutions Placements (QIPs), reinforcing investor confidence.
Earlier debt restructuring has improved leverage metrics and is expected to reduce annual interest costs by approximately ₹300 crore from FY27 onward. The Generics segment recorded 10% sequential and 24% year-on-year revenue growth, supported by continued launches of gLiraglutide across European markets and steady performance in the US formulations portfolio.
Biocon Biologics delivered strong results, with biosimilars revenue rising 9% to ₹2,497 crore. EBITDA climbed 44% to ₹700 crore, reflecting improved product mix and operating efficiencies. During the quarter, the company launched multiple biosimilars globally and advanced its pipeline with three oncology assets—Trastuzumab subcutaneous, Nivolumab, and Pembrolizumab. It also secured global rights for biosimilar Adalimumab and achieved patent settlements enabling entry for Aflibercept and Denosumab biosimilars.
In the US, regulatory approvals were obtained for Tofacitinib extended-release tablets and Everolimus oral suspension tablets. The company’s manufacturing sites in Cranbury and Visakhapatnam received Establishment Inspection Reports from the US FDA.
Syngene International, Biocon’s research services arm, reported continued customer additions and extended its long-standing collaboration with Bristol Myers Squibb through 2035. Biocon continues to expand its global footprint across diabetes, oncology, and immunology, supported by integrated manufacturing capabilities, regulatory progress, and a broad pipeline of biosimilars and specialty therapies.
Biocon Limited is a publicly listed biopharmaceutical company with operations spanning biologics, biosimilars, generics, and complex APIs. Its subsidiary, Biocon Biologics Limited, operates a fully integrated biosimilars business serving patients in more than 120 countries, with a portfolio of commercialized products and an extensive development pipeline.
